Last reviewed · How we verify
SP-102
SP-102 is a synthetic version of delta-9-tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis.
SP-102 is a synthetic version of delta-9-tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis. Used for Chronic pain.
At a glance
| Generic name | SP-102 |
|---|---|
| Sponsor | Scilex Pharmaceuticals, Inc. |
| Drug class | cannabinoid |
| Target | CB1 receptor |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | Phase 3 |
Mechanism of action
It works by activating cannabinoid receptors in the body, which can help to reduce pain and inflammation. SP-102 is designed to provide a more controlled and predictable effect compared to natural THC.
Approved indications
- Chronic pain
Common side effects
- Dizziness
- Nausea
- Fatigue
Key clinical trials
- Corticosteroid Lumbar Epidural Analgesia for Radiculopathy (PHASE3)
- A Research Study to Characterize the Pharmacodynamics and Safety of Repeat Dose SP-102 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SP-102 CI brief — competitive landscape report
- SP-102 updates RSS · CI watch RSS
- Scilex Pharmaceuticals, Inc. portfolio CI